暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
BIIB 渤健公司
- 229.360
- -5.960-2.53%
交易中 05/16 15:21 (美东)
333.94亿总市值28.67市盈率TTM
234.580最高价228.070最低价57.17万股成交量231.600今开235.320昨收1.31亿成交额0.39%换手率28.78市盈率(静)1.46亿总股本319.76052周最高2.20市净率332.69亿流通值189.44052周最低--股息TTM1.45亿流通股480.180历史最高--股息率TTM2.77%振幅2.625历史最低229.948平均价1股每手
盘中分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
由于投资者权衡宏观数据，美国股指涨跌互现；道琼斯指数触及历史新高
周四中午后，美国股指涨跌互现，道琼斯工业平均指数首次触及40,000大关，原因是申请失业救济人数降幅小于预期
Biogen首席执行官在阿尔茨海默氏症药物上涨的同时寻求小额交易
Biogen还放弃了与Ionis在安格尔曼综合症候选药物上的合作
行业更新：医疗保健
周四下午，医疗保健股走软，纽约证券交易所医疗保健指数下跌0.1％，医疗保健精选板块SPDR基金（XLV）小幅下跌。iShares 生物技术 ETF (
Truist Securities：维持Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价由340.00美元调整至340.00美元。
Truist Securities：维持Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价由340.00美元调整至340.00美元。
快讯 | Truist Securities维持对Biogen的买入，维持340美元的目标股价
评论
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$传奇生物(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$Tyra Biosciences(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$渤健公司(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$传奇生物(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$Tyra Biosciences(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$渤健公司(BIIB.US$
$PepGen(PEPG.US$
...
4
Tesla, Visa and Boeing are popping in pre market after reporting their earnings.
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR 标普500指数ETF(SPY.US$ $标普500指数(.SPX.US$ $Visa(V.US$ $波音(BA.US$ $德州仪器(TXN.US$ $渤健公司(BIIB.US$ $爱彼迎(ABNB.US$ $美国银行(BAC.US$ $迪士尼(DIS.US$ $苹果(AAPL.US$ $Meta Platforms(META.US$ $微软(MSFT.US$ $英伟达(NVDA.US$ $台积电(TSM.US$ $超微电脑(SMCI.US$ $Coinbase(COIN.US$ $谷歌-A(GOOGL.US$
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR 标普500指数ETF(SPY.US$ $标普500指数(.SPX.US$ $Visa(V.US$ $波音(BA.US$ $德州仪器(TXN.US$ $渤健公司(BIIB.US$ $爱彼迎(ABNB.US$ $美国银行(BAC.US$ $迪士尼(DIS.US$ $苹果(AAPL.US$ $Meta Platforms(META.US$ $微软(MSFT.US$ $英伟达(NVDA.US$ $台积电(TSM.US$ $超微电脑(SMCI.US$ $Coinbase(COIN.US$ $谷歌-A(GOOGL.US$
From YouTube
5
5
Morning Movers
Gapping up
$特斯拉(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
Gapping up
$特斯拉(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
22
1
... 
The pharma giant $礼来(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
70
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
